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Original article 
Ανάπτυξη DNA εμβολίου για την 
ανοιξιάτικη ιογενή καμία του 
Κυπρίνου 
The development of a DNA vaccine 
for the Spring Viraemia of Carp 
Virus (SVCV) 
Θ.Σ. Κανέλλος
12
, E.M. Ξυλούρη1, Russell P.H.2 Kanellos Th.S.1'2, Xylouri E.M.1, Russell P.H.2 
Π Ε Ρ Ι Λ Η Ψ Η . Η ανοσοποίηση ενός οργανισμού με χο πλασμι-
διακό DNA αποτελεί έναν πολλά υποσχόμενο εναλλακτικό χρόπο 
για να προκληθεί ανοσία έναντι λοιμωδών παραγόντων. Σκοπός της 
παρούσας έρευνας ήταν να μελετηθεί ένα DNA εμβόλιο έναντι της 
Ανοιξιάτικης ιογενους ιαιμίας του κυπρίνου (Spring Viraemia of 
Carp Virus, SVCV), οφειλόμενης σε ραβδοιό, μελετώντας τη γλυ-
κοπρωτείνη G του ίου. Το γονίδιο G ενσωματώθηκε στο πλασμι-
διακό DNA και κλωνοποιήθηκε. Η έκφραση του γονιδίου πραγ­
ματοποιήθηκε με τη βοήθεια των παρακάτω ενισχυτών: 1) του 
κυτταρομεγαλοϊου, 2) του simian virus 40, και 3) της χοίρειας βα­
ριάς αλυσίδας μυοσίνης II Α. Το κλωνοποιημένο γονίδιο G ανα-
συνδυάστηκε είτε με το γονίδιο της E coli, LacZ (ως ανοσοενισχυ-
τικό των Τ λεμφοκυττάρων), είτε με την οδηγό αλληλουχία Ig k-
chain για την παραγωγή της εκκριτικής μορφής της πρωτείνης G. 
Μύες BALB/c ανοσοποιήθηκαν με τα προαναφερθέντα ανασυν-
δυασμένα πλασμίδια και προκλήθηκε έντονη κυτταρική ανοσολο­
γική απάντηση (T-cell proliferative responses) στον SVCV, εν απου­
σία ανιχνεύσιμων αντισωμάτων για τον ιό. Η ομάδα των ποντικών 
που έδωσε εντονότερη ανοσολογική απάντηση ήταν εκείνη που εί­
χε λάβει το γονίδιο LacZ και έτσι αυτό το γονίδιο ελέγχθηκε αργό­
τερα με την παράλληλη έγχυση ενός πλασμιδίου που εξέφραζε την 
κυτταροκίνη Granulocyte Macrophase Colony Stimulating Factor 
(GMCSF). Έτσι, η παράλληλη χορήγηση του πλασμιδίου έκφρα­
σης GMCSF είχε ως αποτέλεσμα την υψηλή ανοσολογική απά­
ντηση έναντι του ίου της Ανοιξιάτικης ιογενους ιαιμίας του κυ­
πρίνου, από τα λεμφοκύτταρα της σπλήνας του ποντικού, με αύ­
ξηση στην παραγωγή και των δυο πρωτεϊνών που είχαν υποστεί 
ανασυνδυασμό (fusion). Αυτά τα αποτελέσματα δείχνουν τη λει­
τουργικότητα των DNA εμβολίων που εξετάστηκαν και την πιθα­
νότητα τα εμβόλια να αναπτύσσουν ανοσολογική προστασία στους 
ιχθυες. 
Λέξεις ευρετηρίασης: Ανοιξιάτικη ιογενής ιαιμία του κυπρίνου, 
DNA εμβόλια 
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ABSTRACT. DNA immunization is a promising approach to 
induce immunity/protection against infectious agents. In the present 
study a DNA vaccine to Spring Viraemia of Carp Virus (SVCV) G 
glycoprotein was investigated. The G gene was cloned intact with 
several promoters namely: 1) the immediate early promoter/ 
enhancer of the human cytomegalovirus; 2) the simian virus 40 
promoter; and 3) the porcine myosin heavy chain IIA promoter. In 
fusion constructs, the G gene was fused either upstream to the 
LacZ gene or downstream to the murine Ig k-chain leader sequence. 
BALB/c mice immunized with the aforementioned plasmids 
produced strong T-cell proliferative responses to the SVCV, in the 
absence of any detectable antibody response. The group that 
responded most robusdy was the one that had received the LacZ 
fusion gene and therefore, this construct was further tested in mice 
with the addition of a plasmid expressing the murine cytokine 
GMCSF. Co-administration of the GMCSF expressing plasmid 
resulted in high SVCV spleenoproliferative responses in mice and 
the development of antibodies to both fused proteins. These results 
indicate the functionality of the constructs and the possibility of 
giving protection in fish. 
Key words: Spring Viraemia of Carp Virus, DNA vaccine, Fish 
1
 Department of Anatomy and Physiology of Farm Animals, Faculty of 
Animal Science, Agricultural University of Athens, 75,1er a Odos str., 
Athens 118 55, Greece 
2
 Departments of Pathology and Infectious Diseases, The Royal 
Veterinary College, Royal College Street, London NW1 OTU, UK 
Ημερομηνία υποβολής: 22.03.2007 
Ημερομηνία εγκρίσεως: 10.05.2007 
Submission date: 22.03.2007 
Approval date: 10.05.2007 
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/03/2020 08:28:28 |
KANELLOS TH.S., XYLOURI E.M., RUSSELL P.H. 35 
INTRODUCTION 
Nucleic acid immunization has been characterized 
as "The third revolution in vaccinology" (Robinson, 
1997), because of its unique way to stimulate both arms 
of the immune system. This vaccine technology has 
already got approval for clinical trials in humans 
(Donnelly et al., 1997), underlying the potential and 
the safety (Robertson, 1994) of this technology to 
prevent or even to cure humans from emerging 
infectious diseases or even diseases like cancer, allergy 
and autoimmunity (Tighe et al., 1998). However, other 
species of significant economic value, besides humans, 
may reap the benefit of DNA vaccines, such as fish. 
Aquaculture is now the most rapidly growing area in 
animal production and presently accounts for more 
than 8% of the total food production worldwide. 
However, because of the fact that these animals are 
reared intensively, they are even more vulnerable to 
infectious pathogens. With regard to fish viral vaccines, 
due to the poor antiviral immunity encountered with 
inactivated preparations and the lack of widespread 
acceptance of attenuated strains as vaccines, the use of 
genetic immunization appears as an attractive 
alternative to control fish diseases (Leong et al., 1997). 
Recently, encouraging reports appeared in the 
literature showing protection of salmonids fish from 
viral pathogens, such as Infectious Haemopoetic 
Necrosis Virus (IHNV) (Anderson et al., 1996) and 
Viral Haemorrhagic Septicaemia Virus (VHSV) 
(Lorenzen et al., 1998), following vaccination with 
naked plasmid DNAs encoding proteins of these 
pathogens. Furthermore, studies employing reporter 
genes have shown that fish respond very well to DNA 
immunization (Rüssel et al., 1998). 
In the present study a DNA vaccine was developed 
for a severe viral disease of the cyprinids, namely Spring 
Viraemia of Carp (SVC). The disease is widespread 
throughout Europe. In the UK, it is a notifiable disease, 
with numerous outbreaks occurring in 1988 (Dixon et 
al., 1994) and 1994 (Roberts, 1994). The disease is 
caused by a rhabdovirus (SVCV), which infects several 
species of carp during spring. Outbreaks of SVC usually 
can result in mortality rates of between 40-90% and 
currently there is no available vaccine to control the 
disease (Dixon, 1997). 
The glycoprotein (G) gene of SVCV, which forms its 
surface peplomers, was chosen because it is the target 
of immunoprophylaxis in all other known members of 
the family Rhabdoviridae (Coll, 1995) for cloning into 
several mammalian expression cassettes. The G gene 
was cloned intact with different viral or mammalian 
promoters, in order to evaluate their efficacy for gene 
immunization. The human cytomegalovirus immediate 
early promoter/enhancer (CMV) and the simian virus 
40 early proteins (SV40) were chosen as viral promoters, 
because both were shown to be very potent in fish 
(Hansen et al., 1991, Anderson et al., 1996). In addition, 
the mammalian porcine myosin heavy chain II A 
promoter (MyHC) (Chang, 2000) was used because it is 
a muscle specific promoter and therefore, it does not 
carry the risk of inappropriate or harmful gene 
expression in other tissues. 
The glycoprotein (G) gene of two fish rhabdoviruses 
namely; Infectious Haemopoetic Necrosis Virus 
(IHNV) (Robinson, 1997) and Viral Haemorrhagic 
Septicaemia Virus (VHSV) (Donnelly et al., 1997), are 
effective as DNA vaccines when driven by the human 
cytomegalovirus immediate early promoter/enhancer 
(CMV). In other studies the full length G gene (Gf) of 
the Spring Viraemia of Carp rhabdovirus (SVCV), as 
well as a truncated form of the G gene (G54), lacking the 
transmembrane region of the protein, were placed into 
a CMV promoter driven plasmid. In vivo analysis of 
these plasmids demonstrated that 1 out of 10 mice with 
the truncated gene and 2 out of 10 with the complete 
gene seroconverted to the encoded glycoprotein 
(Robertson, 1994). 
In the present study we further tested the above 
plasmid encoding the complete SVCV-G protein, in 
addition to four novel constructs. Two of the new 
constructs expressed the G gene under the control of 
either the simian virus 40 early proteins (SV40) 
promoter or the mammalian porcine myosin heavy 
chain II A (MyHC) promoter, both of which promote 
CAT expression in fish (Tighe et al., 1998). A third 
plasmid was constructed to express the G gene as a 
fusion upstream to the LacZ gene, under the control of 
the CMV promoter, in order for the LacZ gene product 
(b-galactosidase) to give Τ help to the G protein in a way 
akin to the hapten-carrier effect (Leong et al., 1997). 
This would also direct the expressed G protein 
towards the cytoplasm, because ß-galactosidase 
accumulates in this cellular compartment (Anderson 
et al., 1996). Finally, the Gf gene was placed downstream 
of the murine Ig k chain leader sequence, in order to 
allow secretion of the expressed protein. The efficacy of 
these DNA constructs was evaluated by their ability to 
induce humoral and cellular immune responses in mice. 
Furthermore, the G gene was fused upstream to the 
LacZ gene in order for LacZ to give Τ help to the G 
protein in a way akin to hapten-carrier (Mitchison, 
1971). This would also direct the expression of the G 
protein towards the cytoplasm, because b-galactosidase 
accumulates in that particular cellular compartment 
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Πίνακας 1. Χαρακτηριστικά των SVCV-G έκφρασης πλασμιδίων για την ανοσοποίηση. Η έκφραση των SVCV-G είχε ρυθμιστεί 
από τους CMV, SV40 και MyHC, αντίστοιχα. Το SVCV-G γονίδιο είχε συγχωνευθεί με το LacZ ή με το Igk στο ίδιο κεντρικό πλα-
σμίδιο (pcDNA3) και η έκφραση είχε καθοδηγηθεί από τον CMV εκκινητή. 
Table 1. Characteristics of the SVCV-G expression plasmids used for immunization. The expression of SVCV-G was controlled by 
CMV, SV40 and MyHC, respectively. The SVCV-G gene was also fused either to the LacZ gene or to the murine Igk leader 
sequences into the same plasmid backbone (pcDNA3), and expression was driven by the CMV promoter. 
Construct 
Name 
Promoter SVCV-G gene Antibiotic 
Resistance gene 
Additional Properties 
pcDNA3/GF 
pcSV40/GF 
pMyHC/GF 
3cDNA3.1/G-LacZ 
pSecTagB/His-GF 
pCMVi-GMCSF 
CMV 
SV40 
MyHC 
CMV 
CMV 
CMV 
Full length 
Full length 
Full length 
G protein chimera 
Full length 
ampR gene 
ampR gene 
ampR gene 
ampR gene 
ampR gene 
kanR gene 
Cytomegalovirus promoter 
Simian Virus 40 promoter 
Porcine myosin heavy chain promoter 
Intact Kozak sequence 
Chimera with B-galactosidase. 
Cytoplasmic expression 
Murine Ig kapper chain leader sequence 
to allow secretion. 
Intact Kozak sequence. 
Expressing the murine 
Granulocyte Macrophage 
Colony Stimulating Factor 
(Davis et al., 1997). The G gene inserted also down­
stream to the murine Ig k-chain leader sequence in order 
to allow secretion of the fusion protein. All the fused 
genes were under the control of the CMV promoter. 
The immunogenicity of these constructs was 
evaluated in a mouse model, because Τ cell responses 
to DNA vaccines are well described in these animals. 
MATERIALS AND METHODS 
Vaccination Vectors 
The Characteristics of all plasmids used in these 
studies are shown in table 1. 
Molecular cloning procedures were essentially as 
described by Sambrook, et al. (Sambrook, et al, 1989). 
Two incomplete genes (pSegG25, pSegG54) of the SVCV 
G glycoprotein as it was confirmed by sequencing 
(results not shown) were kindly provided by Dr 
Bjorklund H., Abo Akademi University, Turku Finland. 
Both genes were inserted by blunt end cloning into the 
CMV mammalian expression vector pcDNA3 (Invitro-
gen) to create the plasmids pcDNA3/G25 and pcDNA3/ 
G 5 4 . The complete SVCV-G gene was prepared by 
removing the 1020 bp 5' end of the pcDNA3/G54 gene by 
digestion with Hindlll andXcml and then by inserting 
it into compatible digested sites of the pcDNA3/G25-
The resulting plasmid was designated pcDNA3/Gf. 
The SV40 promoter from the plasmid pCAT 
(Promega) was -digested with Hindlll and Bglll and 
inserted into compatible restriction sites of the pcDNA3 
in place of CMV to produce the pSV40 plasmid. 
Subsequently, the full length G (Gf) gene was removed 
by digestion with BamHl and Apal from the 
pcDNA3/Gf and transferred into the pSV40 plasmid by 
sticky end cloning. The resulting plasmid was designated 
as pSV40/Gf. The muscle specific promoter MyHC was 
inserted by semi-directional cloning to the pcDNA3/Gf 
after removing the CMV promoter with the restriction 
endonucleases Bglll and Apal. The resulting plasmid 
was named pMyHC/Gf. 
The pcDNA3/Gf was digested with Hindlll and 
Psh AI in order to release part of the G f gene (1424 bp) 
that lacked the stop codon at the 3' end. Subsequently, 
the pcDNA3.1/HisB/LacZ was digested with Kpnl, blunt 
ended with calf intestinal alkaline phosphatase, and re-
digested with Hind III following phenol/ chloroform/ 
Isoamyl alcohol extraction and ethanol precipitation in 
order to release the 6 histidines and the enterokinase 
tag. The 1.4 kb fragment of the G f was then inserted by 
semi-blunt ended cloning into the aforementioned 
plasmid in order to create the plasmid pcDNA3.1/G-
LacZ. 
The Gf gene was removed from the pcDNA3/Gf by 
digestion withÄVzdIII andXbal and inserted in frame 
to a same enzymes digest of pSegTag Β (Invitrogen), 
which contains the murine Ig k chain leader sequence 
upstream of the multiple cloning site to allow secretion 
of the SVCV-G gene. 
All plasmids were sequenced after three repeated 
runs by cycling sequencing to confirm that they were 
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intact to promoters or in frame with the fusion genes 
(results not shown). 
The plasmid pCMVi-mGMCSF, encoding the 
murine cytokine Granulocyte Macrophage Colony 
stimulating Factor (mGMCSF) under the control of 
the CMV, was generously donated form professor 
Johnston SA, Southwestern medical centre, USA. 
All plasmids were purified by alkaline lysis of 
ampicillin treated cultures followed by anion-exchange 
chromatography (Giga-Prep, Qiagen) and then 
resuspended at lmg/ml in endotoxin-free saline (Sigma) 
for injection. 
Transient Transfection 
To determine the expression of the Gf gene in the 
aforementioned plasmids, Epithelioma Papulosum 
Carpio cells (EPC) were transfected in a 12 well cell 
culture plate (Nunc) using Lipofectamin (Gibco-BRL, 
Life technologies) and cultured for 3 days. The cells 
were then fixed with acetone and stained with an anti-
SVCV rabbit polyclonal antibody R116, generously 
donated by Dr Dixon, MAFF, Weymouth, which has 
neutralizing activity against SVCV, and with goat anti-
rabbit IgG labelled with HRP (Dako). Transfected cells 
were then visualized with a chromatogen (HRPO) 
(Czerkinsky et al., 1988) under an inverted microscope. 
For the plasmid encoding the fusion Gf-LacZ gene, 
an additional in situ, staining with X-gal was performed 
in order to determine the expression of the b-
galactosidase (Wells et al., 1997). 
TNT® Coupled Reticulosyte Lysate Systems 
The ability of the pcDNA3 vector to express SVCV 
glycoprotein was determined using a TNT® coupled 
reticulosyte lysate system (Promega), which utilizes the 
T7 RNA polymerase to transcribe the inserted gene. 
Translation reaction products were resolved by 
reducing SDS-Polyacylamide Gel Electrophoresis 
(SDS-PAGE) on a 15% gel, and then electro-blotted 
onto nitrocellulose membrane (Sambrook et al., 1989). 
The membrane was probed with the R116 anti-SVCV 
rabbit antiserum, and then probed with an anti-
rabbit/alkaline phosphatase conjugated secondary 
antiserum. Finally, the secondary antibody was detected 
by NBT/BCIP staining as per manufacturer's 
instructions (Promega). 
Northern Blot Analysis 
Total RNA was extracted from transfected cells 
(RNeasy kit Qiagen,) and following electrophoresis, 
RNA was fixed to a Hybond-N+ membrane (Amer-
sham, Life Science) (Wells et al., 1997). The blot was 
subsequently hybridized with a specific SVCV-G probe 
overnight at 60 °C. The probe was prepared by excising 
the l.ókb Gf gene from the pcDNA3Gf withHindlll and 
Xbal. Labelling of probe and subsequent hybridization 
detection were performed by an ECL random prime 
labelling and detection system, version II kit membrane 
(Amersham, Life Science). 
Intramuscular Injection 
Experiment 1: Male BALB/c mice aged 6-8 weeks 
were obtained from Harlan Olac, UK. Groups of 6 mice 
received either 50 μg of the empty plasmid (pcDNA3) 
or 50 μg of plasmids encoding the SVCV-G protein 
either under the control of different promoters 
(pcDNA3/Gf, pSV40/Gf, pMyHC/Gf) or as fusion gene 
(pSecTagB/Gf, pcDNA3.1/Gf-LacZ). Half the plasmid 
was injected into the middle of each BaCl2 pretreated21 
anterior tibial muscle (TA) using an insulin syringe 
fitted with a 28/29g needle, under general anaesthesia. 
The mice were re-immunized 4 times at monthly 
intervals. Tail blood was collected at 4, 8, 12, 16, 20 
weeks after the first injection. 
Experiment 2: Two groups of five female BALB/c 
mice were injected either with 100 μg empty plasmid 
(pcDNA3) or with 100 μg of an equal mixture of the 
plasmids pcDNA3.1/G-LacZ and pCMVi-mGMCSF. 
DNA injections were performed as before, except that 
this time recipient TA muscles had not received any 
pretreatment. One month after the injections, mice 
were euthanised and serum samples were tested for 
antibody, while their spleens were processed for T-cell 
stimulation. 
Anti-ß-Galactosidase ELISA 
Serum samples were analyzed by ELISA against 
purified £. coli ß-galactosidase VIII protein (Sigma) as 
described previously (Rüssel et al., 1998). In brief 
twofold dilutions of mice sera at 1:25 to 1:12800 were 
reacted for 1 hour at 37 °C and binding was detected 
using a rabbit anti-mouse conjugate (Dako). The serum 
titers calculated as the reciprocal of the serum dilution 
that gave an OD492 of three standard deviations above 
that of the negative control mice. A mouse monoclonal 
anti-ß-galactosidase antibody (Sigma) was used as a 
positive control with an end point of 106. 
Anti-SVCV ELISA 
In principals the anti-SVCV ELISA was identical to 
the aforementioned anti-ß-gal ELISA with the only 
exception that the coating antigen was concentrated 
SVCV from supernatant of infected cells, which had 
been centrifuged at 20.000rpm for 2 hours. The rabbit 
antiserum R116 (positive control) reacted to a titer of 
105. 
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Anti-SVCV Antibody Assay 
Sera from DNA injected mice were 
analyzed for antibodies to SVCV by 
indirect Monolayer Immunoperoxidase 
Assay (IPMA) (Hansen et al., 1991) on 
overnight infected EPC cells with 102 pfu 
SVCV (American type culture collection: 
ATCC, VR-1390). Cells were then fixed, 
blocked (PBST-B) and test serum of three 
fold dilution starting at 1/25 was added. 
Chromatogenic detection with a rabbit 
anti-mouse IgG-HRP conjugate was as 
earlier described. The rabbit antiserum 
R116 (positive control) stained foci to a 
titer of 105. 
Τ Lymphocyte Proliferation Assay 
Mouse spleens were aseptically 
removed and were made to a single cell 
suspension in a supplemented RPMI-1640 
medium (Gibco, BRL) (Partidos and 
Stewart, 1990). Cultures were then 
stimulated either with ΙΟΟμΙ (neat) 
supernatant of SVCV infected EPC cells 
or with 10μg recombinant ß-galactosidase. 
Controls included cells stimulated with 
medium or 0 ^ g / m l phytohaemaglutinin 
(PHA) (Sigma). The stimulation index was 
defined as the ratio of counts per minute 
(cpm) of stimulated and medium-only 
cultures. 
RESULTS 
57 kDa 
49kDa 
37 kDa 
In Vitro Expression of DNA Plasmids 
Encoding the SVCV-G Glycoprotein 
Initial attempts to express the 
aforementioned constructs in vitro by 
employing the liposome mediated 
transfection method were without 
apparent success, because the rabbit 
antiserum stained normal cells by the 
indirect monolayer peroxidase assay and 
reacted to many proteins in cells and foetal 
calf serum by western blotting. Therefore, the lack of a 
monospesific serum to the SVCV-G protein made 
problematic the detection of the expressed protein 
either in vitro or in vivo. The positive control plasmid 
that encoded the Escherichia coli LacZ gene was highly 
expressed as reported before (Rüssel et al., 1998). 
The functionality of these plasmids was determined 
in vitro by employing several diverse approaches. The 
efficiency of the pcDNA3/G vectors to express the 
Εικόνα 1. In vitro έκφραση των τριών προϊόντων pcDNA3/G25, pcDNA3/G54 και 
pcDNA3/Gf, που κωδικοποιούν είτε τις δυο ατελείς μορφές της SVCV-G πρω­
τεΐνης (G2 5 και G54) είτε την πλήρη μορφή της (Gf), χρησιμοποιώντας το ενδο­
θηλιακό σύστημα λΰσης μεταγραφής-μετάφρασης TNT. Από την ανάλυση των 
προϊόντων αντίδρασης με τη μέθοδο Western blot φάνηκε η έκφραση των δια­
φορετικών μεγεθών της SVCV-G πρωτεΐνης στα προβλεπόμενα μοριακά βάρη. 
Το γονίδιο της λουσιφεράσης χρησιμοποιήθηκε ως αρνητικός μάρτυρας. 
Figure 1. In vitro expression of the three constructs designated as pcDNA3/G25, 
pcDNA3/G54 and pcDNA3/Gf, encoding either the two incomplete forms of the 
SVCV-G protein (G2 5 and G54) or its full length (Gf) by using the coupled trans­
cription/ translation reticulocyte lysate system TNT. Western blot analysis of the 
reaction products revealed the expression of the different lengths of the SVCV-
G protein at the predicted molecular weights. Luciferase gene was used as negative 
control. 
several lengths of the G gene was determined by using 
a rabbit reticulosyte lysate system. As shown in figure 1, 
the G protein was expressed at the expected molecular 
weight and was recognized by the virus-specific serum 
R116. For plasmids that did not contain the T7 promo­
ter, G gene transcriptional activity was determined by 
detecting mRNA expression following transfection 
(figure 2). Moreover, the limited expression of the LacZ 
gene from the plasmid expressing the fusion gene G-
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SPECIFIC TO THE 
SVCV-G GENE 
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Εικόνα 2. Ανάλυση με τη μέθοδο Northern blot των συνολικών RNA δειγμάτων, που απομονώθηκαν από τα μετασχηματισμένα κύτ­
ταρα, στα οποία είχαν εισαχθεί τα πλασμίδια pPMyHC/Gf και pSV40/Gf. 
Figure 2. Northern blot analysis of total RNA samples extracted from transfected cells with the plasmids pPMyHC/Gf and pSV40/Gf. 
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Εικόνα 3. In situ X-gal χρώση των μετασχηματισμένων EPC κυττάρων με το πλασμίδιο pcDNA3.1/Gf-LacZ, το οποίο εκφράζει και τα 
δυο ανασυνδυασμενα γονίδια (Gf-LacZ). 
Figure 3. In situ X-gal staining on transfected EPC cells with the plasmid pcDNA3.1/Gf-LacZ, which expresses both genes as a fusion. 
LacZwas apparent after transfection studies (figure 3), 
attesting that the G gene, which was upstream of the 
LacZ, was indeed expressed but it could not be detected. 
Antibody Responses 
At the end of the first experiment, antibody to 
SVCV-G protein and b-galactosidase was detected in 
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Εικόνα 4. Ανοσοποιητική απάντηση του μυός, μετά από ενδομυϊκή έγχυση του pcDNA3,l/Gf-LacZ, ήχαν ειδική στον ιό, όπως επιβε­
βαιώθηκε με ΙΡΜΑ. 
Figure 4. The mouse antibody response following the intramuscular administration of the pcDNA3.1/Gf-LacZ was virus specific as it was 
confirmed by IPMA. 
only one out of six mice. The mouse that responded 
positively was after the last bleeding, from the group 
which had been immunized with the plasmid 
pcDNA3.1/G-LacZ. The antibody response was specific 
to the SVCV at a serum dilution of 1/50 and to the β-
galactosidase at a dilution of 1/200 as determined by 
ELISA. 
In the second experiment, where mice co-injected 
with a mixture of the most prominent plasmid 
(pcDNA3.1/G-LacZ) and a plasmid encoding the 
murine cytokine GMCSF, four out of five mice 
responded positively to the SVCV with a constant 
serum dilution of 1/25, and to the b-gal in serum 
dilutions of between 1/25 - 1/50 with a mean of 1/30. 
Obviously the co-administration of the mGMCSF 
ameliorated the antibody response to both proteins 
after a single injection, although titers were lower than 
that observed from the only responded mouse in the 
first experiment. 
Proliferative Τ cell Responses 
Surprisingly normal and immune mouse splenocytes 
proliferated in vitro after re-stimulation with super­
natant from SVCV infected cells. The overall 
stimulation indices were higher after injection with 
plasmid DNAs expressing the SVCV-G protein, 
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T-CELL PROLIFERATION 
120 
pcDNA3/G PSV40/G pPMyHC/G pSecTag/His/G pcDNA3 1/G-LacZ pcDNA3 
PLASMID DNAs 
Εικόνα 5. Ανοσοποιητική απάντηση των λεμφοκυττάρων της σπλήνας του μυός που ενοφθαλμίστηκε με pcDNA3/G, pSV40/G, 
pPMyHC/G, PSecTag/His/G, pcDNA3.1/G-LacZ και pcDNA3 (αρνητικός μάρτυρας). Τα αποτελέσματα εκφράζονται ως ο γεωμετρι­
κός μέσος όρος των καλλιεργειών εις τριπλούν. 
Figure 5. Proliferative responses of splenocytes from mice vaccinated with pcDNA3/G, pSV40/G, pPMyHC/G, PSecTag/His/G, 
pcDNA3.1/G-LacZ and pcDNA3 as negative control. Results are expressed as the geometric mean of triplicate cultures. 
suggesting the in vivo functionality of these constructs. 
The background observed from the negative control 
mice was attributed to the presence of mitogenic 
substances in the supernatant (eg. viral RNA) of the 
infected cells (figure 5). The cpm values of the untreated 
cultures were between 160 and 635, while the same 
values from the mice injected with the negative control 
plasmid were between 3.316 and 9.310. The cpm figure 
from the mice immunized with constructs expressing 
the SVCV-G protein was between 6.985 and 27.530. 
Concerning the efficacy of the plasmids with the 
different promoters at inducing proliferative 
splenocytes, the CMV was better than the other two, 
although the differences were insignificant. The plasmid 
pSecTagB/Gf, which secreted the G-protein, produced 
the weakest response, as was the case with the 
glycoprotein of the rabies virus where the secreted form 
of the protein conferred less protection in mice than the 
anchored form (Xiang et al., 1995). By far the highest T-
cell response was achieved by the plasmid expressing the 
fusion Gf-LacZ gene and it was double. 
In the second experiment, mice splenocytes 
proliferated again in the presence of the SVCV or after 
cultivation with the recombinant b-galactosidase. The 
stimulation indices for the S VCV were lower in relation 
to results from the first experiment and this was 
probably due to differences in the immunization regime. 
The background in that instant was not as high as in the 
first experiment; mainly due to the repeated freezed-
thawed of the SVCV supernatant, which should had 
resulted in the degradation of the viral RNA. The cpm 
numbers from the unstimulated cultures was between 
456 and 687. The cpm numbers from the negative 
control wells were between 1.070 and 1.210 when they 
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stimulated with SVCV and between 450 to 610 when 
they stimulated with recombinant b-gal protein. The 
corresponding values from the splenocytes of mice 
injected with the tested plasmids, were between 4.676 
and 6.139 when restimulated with SVCV and 14.213-
17.149 when they cultured with ß-gal protein . 
DISCUSSION 
The present study demonstrates for the first time 
immune response to the SVCV following DNA 
immunization of mice. The presence of proliferative 
responses, to the whole virus, in the absence of any 
consistent or low antibody, is not uncommon for DNA 
vaccination, since many workers have shown T-cell 
immunity following by protection in several animal 
models, although these animals had no or very low 
antibody titers (Fynan et al., 1993, Martins et al., 1995, 
Oliveira et al., 1997). More importantly, studies with 
experimentally inactivated SVCV vaccines have shown 
that the development of virus neutralizing antibody in 
fish was not accompanied by protective immunity and 
therefore T-cell immunity should be critical for the 
protection of fish from this disease (Fijan, 1988). 
However, the co-administration of the mGMCSF, as it 
has been reported from other studies (Gerloni et al., 
1998), increased the antibody response to the SVCV-G 
protein. We have now used mixtures of the above 
constructs to induce Τ cell proliferation in fish, and 
more importantly we have shown that the mCMCF is 
also active in fish (unpublished observations). In recent 
studies, similar DNA vaccines were also tested in the 
target animals with very encouraging results (Kanellos 
et al., 2006). 
SVCV appears mitogenic to normal mouse 
splenocytes. The mitogenicity of negative stranded 
RNA viruses to lymphocytes has been reported 
previously (Rüssel, 1988) and may be attributable to the 
virus cross-linking cells or its stable double stranded 
replicative form inducing cytokines. 
The low levels of antibody to the SVCV G-protein 
are assumed to be due to the poor expression of the G-
gene. The low levels of the SVCV-G expression may 
relate to the toxicity of the gene or to the down-
regulation of the host cell function by the protein (Barry 
and Johnston, 1997). More research will be needed 
either on the development of a minigene expressing B-
cell neutralizing epitopes or to the sequence optimi-
zation of the gene for mammalian expression, as in the 
case of HIV (Andre et al., 1998). Nevertheless, a 
challenge experiment in a licensed establishment (since 
the disease is notifiable for the UK) will clarify the 
potential of this prototype vaccine. However, when the 
virus from the supernatant of infected cells was 
repeatedly freezed-thawed, its mitogenicity diminished, 
probably because of the RNA degradation. 
Davis and co workers had shown that the co-
administration of two plasmids, one expressing a low-
immunogenic protein, such as the luciferase, and a 
second one encoding a strong immunogen, like the ß-
galactosidase, resulted in the early clearance of the 
myocytes expressing the luciferase gene (Davis et al., 
1997). This, they postulated, was due to the local 
accumulation of cytotoxic Τ cells against myocytes 
expressing ß-galactosidase. We hypothesized that the 
direct fusion of problematic genes, such as the SVCV-
G gene, with the immunogenic LacZ gene will ensure 
the co-expression of both genes in the same cell and 
therefore will increase the immunogenicity of the 
problematic protein by attracting antigen presenting 
cells and Τ cells to the transfected myocytes. Results 
presented herein demonstrated that the direct fusion of 
the G-gene with the LacZ gene increased the T-cell 
response to the SVCV G-protein and it was present for 
both proteins as clarified from the second experiment. 
The higher stimulation indices that observed for the β-
galactosidase in relation to the SVCV should represent 
the differences in the purity of the material used for 
proliferation. This approach therefore can be used as an 
alternative way to increase the immunogenicity of other 
genes, where the expression or the antigenicity of 
expressed proteins is low. Furthermore, the theoretical 
problem of competition between genes was not detected 
(unpublished observations) and this has been attested by 
other researchers (Grifantini et al., 1998). 
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